Our latest paper in collaboration with Pfizer on the role of OCT2/MATE in creatinine clearance is accepted in JPET.
Our client wished to evaluate the retinal toxicity of a pair of lead compounds and understand how each affects the retina.
The client needed a retina model to rapidly evaluate the retinal toxicity of two molecules and understand possible differences. We proposed to determine how each compound affects cell viability as well as the cellular composition of our iPSC-derived retinal organoid model.
The experimental plan involved testing compound induced toxicity using mature healthy retinal organoids differentiated for 150 days exposing the organoids for 72 hours. The readouts included retinal organoid viability assays and immunofluorescence with 6 key retinal markers to assess the organoid cells composition (ganglion cells, photoreceptors, amacrine cells, horizontal cells and Muller glia).
The study includes the experimental phase, data processing and analysis as well as a data summary presentation.
DATASET: 4 compounds, 1 positive control, 100 retinal organoids, 7 immunofluorescence staining per compound, ATP depletion and LDH release for each compound
The study was completed in just under 2 months.
We delivered a robust dataset which contained a large set of immunofluorescence images
Our analysis confirmed retinal toxicity of one of the compounds and we provided insights to the client as to how the compound affects different cell types.